Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by socio-communicational deficits and restricted/repetitive behaviors. There is no approved pharmacotherapy for the treatment of these core symptoms. Cariprazine is an oral dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist. This study investigated the effects of cariprazine in a preclinical ASD model.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Biological Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2020 Published by Elsevier Inc.